247 related articles for article (PubMed ID: 32948345)
1. Advances in urologic oncology "OncoForum": The best of 2019.
Gómez-Veiga F; Alcaraz Asensio A; Burgos Revilla J; Cózar Olmo J
Actas Urol Esp (Engl Ed); 2020 Nov; 44(9):586-596. PubMed ID: 32948345
[TBL] [Abstract][Full Text] [Related]
2. Developments in urologic oncology «OncoForum»: The best of 2015.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
Actas Urol Esp; 2016; 40(6):361-9. PubMed ID: 27061663
[TBL] [Abstract][Full Text] [Related]
3. Developments in urologic oncology "OncoForum": The best of 2017.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
Actas Urol Esp (Engl Ed); 2018 Oct; 42(8):488-498. PubMed ID: 29935800
[TBL] [Abstract][Full Text] [Related]
4. Developments in urologic oncology «OncoForum»: The best of 2016.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo JM
Actas Urol Esp; 2017 Nov; 41(9):543-551. PubMed ID: 28734596
[TBL] [Abstract][Full Text] [Related]
5. Advances in uro-oncology "OncoForum": the best of 2013.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
Actas Urol Esp; 2014 Oct; 38(8):491-8. PubMed ID: 24731526
[TBL] [Abstract][Full Text] [Related]
6. Developments in urologic oncology 'OncoForum': The best of 2014.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
Actas Urol Esp; 2015 Jun; 39(5):271-8. PubMed ID: 25770399
[TBL] [Abstract][Full Text] [Related]
7. Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla JM; Cózar-Olmo FJ
Actas Urol Esp (Engl Ed); 2022 May; 46(4):214-222. PubMed ID: 34844900
[TBL] [Abstract][Full Text] [Related]
8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
9. [Advances in uro-oncology «Oncoforum»: the best of 2011].
Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
Actas Urol Esp; 2012 Oct; 36(9):507-14. PubMed ID: 22520042
[TBL] [Abstract][Full Text] [Related]
10. [Combination radiotherapy-immunotherapy in genitourinary cancer].
Ollivier L; Guimas V; Rio E; Vaugier L; Masson I; Libois V; Labbé M; Fradin D; Potiron V; Supiot S
Cancer Radiother; 2021 Oct; 25(6-7):565-569. PubMed ID: 34391648
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
12. [Update urooncology: news with clinical relevance from major scientific meetings 2012].
Hegele A; Skrobek L; Schrader AJ
Aktuelle Urol; 2012 Dec; 43(6):376-87. PubMed ID: 23254351
[TBL] [Abstract][Full Text] [Related]
13. [Urologic malignancies in renal transplant candidates and recipients].
Kleinclauss F; Thuret R; Murez T; Timsit MO
Prog Urol; 2016 Nov; 26(15):1094-1113. PubMed ID: 27665407
[TBL] [Abstract][Full Text] [Related]
14. ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.
Palou J; Wood D; Bochner BH; van der Poel H; Al-Ahmadie HA; Yossepowitch O; Soloway MS; Jenkins LC;
Eur Urol; 2013 Jan; 63(1):81-7. PubMed ID: 22938869
[TBL] [Abstract][Full Text] [Related]
15. The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.
Solinas C; Chanzá NM; Awada A; Scartozzi M
Cancer Treat Rev; 2017 Feb; 53():138-145. PubMed ID: 28113097
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
17. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in immuno-oncology and its application to urological cancers.
Mataraza JM; Gotwals P
BJU Int; 2016 Oct; 118(4):506-14. PubMed ID: 27123757
[TBL] [Abstract][Full Text] [Related]
19. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
20. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
